TG Therapeutics, Inc. (TGTX) shareholders
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 21,190,534 | 13.80% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Portfolio Management | 8,400,210 | 5.26% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 8,100,619 | 5.10% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TGTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 22,050,045 | 14.41% | $1.21B | −202,885 | 0.02% |
| Vanguard Portfolio Management LLC | 7,963,266 | 5.20% | $437.50M | −310,713 | 0.02% |
| State Street Corp | 7,786,471 | 5.09% | $427.79M | −863,295 | 0.01% |
| Vanguard Capital Management LLC | 6,149,403 | 4.02% | $337.85M | −453,855 | 0.01% |
| Geode Capital Management, LLC | 3,642,216 | 2.38% | $200.14M | +142,300 | 0.01% |
| D. E. Shaw & Co., Inc. | 3,400,808 | 2.22% | $186.84M | +2,810,761 | 0.09% |
| Soleus Capital Management, L.P. | 2,927,895 | 1.91% | $160.86M | −1,101,424 | 5.54% |
| Price T Rowe Associates Inc /Md/ | 2,767,656 | 1.81% | $152.06M | +2,134,922 | 0.02% |
| Clearbridge Investments, LLC | 2,650,192 | 1.73% | $145.60M | −560,738 | 0.12% |
| Congress Asset Management Co /Ma | 2,600,123 | 1.70% | $142.85M | +432,042 | 0.88% |
| Two Sigma Investments, LP | 2,468,971 | 1.61% | $135.65M | +926,659 | 0.10% |
| Goldman Sachs Group Inc | 2,314,279 | 1.51% | $127.15M | +26,591 | 0.01% |
| Pictet Asset Management Holding SA | 1,785,951 | 1.17% | $98.12M | +38,578 | 0.09% |
| Jane Street Group, LLC | 1,752,646 | 1.15% | $96.29M | −289,023 | 0.01% |
| Nuveen, LLC | 1,625,876 | 1.06% | $89.33M | +178,798 | 0.02% |
| Morgan Stanley | 1,601,714 | 1.05% | $88.00M | +193,544 | 0.00% |
| Hood River Capital Management LLC | 1,600,510 | 1.05% | $87.93M | +31,339 | 0.64% |
| Northern Trust Corp | 1,537,059 | 1.00% | $84.45M | +94,480 | 0.01% |
| Charles Schwab Investment Management Inc | 1,313,103 | 0.86% | $72.14M | +18,048 | 0.01% |
| Bank Of America Corp /De/ | 1,309,788 | 0.86% | $71.96M | −151,514 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 428 | 111M | 72.6% | 105 / 149 | 120 / 35 | 16M | 10M |
| Q1 2026 | 365 | 105M | 68.9% | 68 / 137 | 106 / 49 | 27M | 9M |
| Q4 2025 | 352 | 103M | 67.5% | 61 / 130 | 111 / 55 | 12M | 8M |
| Q3 2025 | 354 | 99M | 64.8% | 49 / 103 | 136 / 47 | 10M | 13M |
| Q2 2025 | 356 | 102M | 66.9% | 45 / 142 | 107 / 63 | 12M | 9M |
| Q1 2025 | 376 | 99M | 64.8% | 85 / 116 | 119 / 36 | 12M | 9M |
| Q4 2024 | 331 | 97M | 63.5% | 83 / 99 | 97 / 55 | 11M | 15M |
| Q3 2024 | 308 | 103M | 67.0% | 97 / 94 | 73 / 44 | 38M | 18M |
| Q2 2024 | 259 | 94M | 61.4% | 50 / 91 | 70 / 30 | 15M | 14M |
| Q1 2024 | 241 | 93M | 60.8% | 46 / 79 | 74 / 36 | 16M | 15M |
| Q4 2023 | 235 | 92M | 60.4% | 40 / 79 | 70 / 39 | 21M | 20M |
| Q3 2023 | 236 | 91M | 59.2% | 48 / 100 | 51 / 54 | 29M | 27M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
306 funds held TGTX in Q2 2026, 64% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TGTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7,940,193 | 5.19% | $436.23M | 0.39% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,377,027 | 2.86% | $240.47M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,736,999 | 2.44% | $205.31M | 0.25% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,160,785 | 2.06% | $173.65M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,135,715 | 1.40% | $117.34M | 1.09% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,820,899 | 1.19% | $100.04M | 0.21% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,591,147 | 1.04% | $82.79M | 0.24% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,511,626 | 0.99% | $83.05M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,343,991 | 0.88% | $73.84M | 0.48% | Jun 30, 2026 |
| Congress Small Cap Growth Fund | 1,300,000 | 0.85% | $67.64M | 3.37% | Jul 31, 2026 |
| Vanguard Explorer Fund | 1,285,751 | 0.84% | $66.90M | 0.30% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 1,209,260 | 0.79% | $66.44M | 0.39% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1,184,420 | 0.77% | $65.07M | 0.79% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,013,200 | 0.66% | $55.67M | 0.38% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 933,712 | 0.61% | $51.30M | 0.77% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael S. Weiss | CEO, Director | 22,846,168 | 14.93% | Jan 9, 2026 |
| Sean A. Power | CFO | 798,111 | 0.52% | Jan 9, 2026 |
| Laurence N. Charney | Director | 168,640 | 0.11% | Sep 14, 2026 |
| Sagar Lonial | Director | 94,061 | 0.06% | Jun 15, 2026 |
| Yann Echelard | Director | 223,816 | 0.15% | Jun 15, 2026 |
| Kenneth Hoberman | Director | 279,653 | 0.18% | Jun 15, 2026 |
| Daniel Hume | Director | 192,748 | 0.13% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Laurence N. Charney Director | Sep 10, 2026 | Sale | −5,000 | $54.96 | $274.80K | 168,640 |
| Laurence N. Charney Director | Aug 7, 2026 | Gift | −500 | – | – | 174,090 |
| Laurence N. Charney Director | Aug 7, 2026 | Gift | −450 | – | – | 173,640 |
| Laurence N. Charney Director | Aug 6, 2026 | Gift | −5,100 | – | – | 174,590 |
| Laurence N. Charney Director | Jan 29, 2026 | Gift | −13,197 | – | – | 179,690 |
| Laurence N. Charney Director | Jan 28, 2026 | Gift | −30,000 | – | – | 192,887 |
| Sean A. Power CFO | Jan 8, 2026 | Award | +90,000 | – | – | 798,111 |
| Michael S. Weiss CEO, Director | Jan 8, 2026 | Award | +622,000 | – | – | 9,778,086 |
| Yann Echelard Director | Nov 24, 2025 | Sale | −5,000 | $32.57 | $162.85K | 223,816 |
| Michael S. Weiss CEO, Director | Nov 5, 2025 | Gift | −803,717 | – | – | 9,156,086 |
| Michael S. Weiss CEO, Director | Nov 5, 2025 | Gift | −3,865,126 | – | – | 9,959,803 |
| Sagar Lonial Director | Sep 11, 2025 | Sale | −20,852 | $32.24 | $672.27K | 94,061 |
| Yann Echelard Director | Jun 13, 2025 | Sale | −10,000 | $36.94 | $369.40K | 228,816 |
| Daniel Hume Director | Jun 12, 2025 | Award | +14,718 | – | – | 192,748 |
| Yann Echelard Director | Jun 12, 2025 | Award | +14,718 | – | – | 238,816 |
| Sagar Lonial Director | Jun 12, 2025 | Award | +14,718 | – | – | 114,913 |
| Laurence N. Charney Director | Jun 12, 2025 | Award | +21,408 | – | – | 222,887 |
| Kenneth Hoberman Director | Jun 12, 2025 | Award | +14,718 | – | – | 279,653 |
| Daniel Hume Director | Mar 17, 2025 | Gift | −62,459 | – | – | 178,030 |
| Laurence N. Charney Director | Mar 10, 2025 | Gift | −6,000 | – | – | 201,479 |
| Michael S. Weiss CEO, Director | Jan 29, 2025 | Award | +750,000 | – | – | 13,824,929 |
| Sean A. Power CFO | Jan 29, 2025 | Award | +87,500 | – | – | 708,111 |
| Sean A. Power CFO | Jan 6, 2025 | Sale | −10,021 | $28.53 | $285.90K | 660,611 |
| Sean A. Power CFO | Jan 3, 2025 | Sale | −11,337 | $30.29 | $343.40K | 670,632 |
| Laurence N. Charney Director | Nov 12, 2024 | Gift | −5,000 | – | – | 207,479 |
| Sagar Lonial Director | Nov 11, 2024 | Sale | −5,000 | $30.44 | $152.20K | 100,195 |
| Laurence N. Charney Director | Nov 11, 2024 | Sale | −25,000 | $30.20 | $755.00K | 212,479 |
| Yann Echelard Director | Nov 5, 2024 | Sale | −20,000 | $24.48 | $489.60K | 224,098 |
| Sagar Lonial Director | Jun 20, 2024 | Sale | −16,348 | $16.87 | $275.79K | 105,195 |
| Sagar Lonial Director | Jun 19, 2024 | Award | +22,250 | – | – | 121,543 |
| Kenneth Hoberman Director | Jun 19, 2024 | Award | +22,250 | – | – | 264,935 |
| Daniel Hume Director | Jun 19, 2024 | Award | +22,250 | – | – | 240,489 |
| Yann Echelard Director | Jun 19, 2024 | Award | +22,250 | – | – | 244,098 |
| Laurence N. Charney Director | Jun 19, 2024 | Award | +22,250 | – | – | 237,479 |
| Sagar Lonial Director | Jun 17, 2024 | Sale | −9,585 | $16.39 | $157.10K | 99,293 |
| Sagar Lonial Director | Mar 13, 2024 | Sale | −5,000 | $15.94 | $79.70K | 108,878 |
| Laurence N. Charney Director | Mar 12, 2024 | Sale | −22,000 | $15.97 | $351.34K | 215,229 |
| Michael S. Weiss CEO | Jan 6, 2024 | Award | +1,001,908 | – | – | 13,074,929 |
| Laurence N. Charney Director | Jan 5, 2024 | Sale | −17,500 | $19.03 | $333.03K | 237,229 |
| Sean A. Power CFO | Jan 5, 2024 | Award | +75,000 | – | – | 681,969 |
| Sean A. Power CFO | Jan 3, 2024 | Sale | −47,867 | $16.91 | $809.43K | 606,969 |
| Sean A. Power CFO | Dec 15, 2023 | Gift | −40,000 | – | – | 641,969 |
| Yann Echelard Director | Sep 28, 2023 | Award | +20,000 | – | – | 221,848 |
| Daniel Hume Director | Sep 28, 2023 | Award | +20,000 | – | – | 218,239 |
| Kenneth Hoberman Director | Sep 28, 2023 | Award | +20,000 | – | – | 242,685 |
| Sagar Lonial Director | Sep 28, 2023 | Award | −20,000 | – | – | 113,878 |
| Laurence N. Charney Director | Sep 28, 2023 | Award | +20,000 | – | – | 254,729 |
| Michael S. Weiss CEO and President, Director | Aug 11, 2023 | Buy | +100,000 | $10.13 | $1.01M | 12,073,021 |
| Sagar Lonial Director | Jun 23, 2023 | Sale | −34,854 | $23.37 | $814.54K | 93,878 |
| Sean A. Power Chief Financial Officer | Jun 2, 2023 | Sale | −73,647 | $26.70 | $1.97M | 654,836 |
| Sean A. Power Chief Financial Officer | Mar 12, 2023 | Award | +85,000 | – | – | 728,483 |
| Michael S. Weiss CEO and President, Director | Mar 12, 2023 | Award | +985,000 | – | – | 11,973,021 |
| Yann Echelard Director | Jan 6, 2023 | Buy | +9,000 | $10.64 | $95.76K | 201,848 |
| Laurence N. Charney Director | Jan 4, 2023 | Sale | −30,000 | $11.10 | $333.00K | 234,729 |
| Kenneth Hoberman Director | Jul 20, 2022 | Award | +43,732 | – | – | 222,685 |
| Sagar Lonial Director | Jul 20, 2022 | Award | +43,732 | – | – | 128,732 |
| Yann Echelard Director | Jul 20, 2022 | Award | +43,732 | – | – | 192,848 |
| Sean A. Power Chief Financial Officer | Jul 20, 2022 | Award | +75,000 | – | – | 643,483 |
| Laurence N. Charney Director | Jul 20, 2022 | Award | +43,732 | – | – | 264,729 |
| Daniel Hume Director | Jul 20, 2022 | Award | +43,732 | – | – | 198,239 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TG Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 192,960 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Laurence N. Charney Director | Sep 10, 2026 | 5,000 | $274.79K | Sep 10, 2026 | Restricted Stock Vesting |
| Yann Echelard Director | Nov 24, 2025 | 5,000 | $162.85K | Nov 24, 2025 | Restricted Stock Vesting |
| Sagar Lonial Director | Sep 11, 2025 | 20,852 | $672.23K | Sep 11, 2025 | Restricted Stock Vesting |
| Yann Echelard Director | Jun 13, 2025 | 10,000 | $369.35K | Jun 13, 2025 | Restricted Stock Vesting |
| Sean A. Power Officer | Jan 6, 2025 | 10,021 | $285.94K | Jan 6, 2025 | Restricted Stock Vesting |
| Sean A. Power Officer | Jan 3, 2025 | 11,337 | $343.45K | Jan 3, 2025 | Restricted Stock Vesting |
| Sagar Lonial Director | Nov 12, 2024 | 5,000 | $152.20K | Nov 11, 2024 | Restricted Stock Vesting |
| Laurence N. Charney Director | Nov 12, 2024 | 25,000 | $754.87K | Nov 11, 2024 | Restricted Stock Vesting |
| Laurence N. Charney Director | Nov 12, 2024 | 25,000 | $754.87K | Nov 11, 2024 | Restricted Stock Vesting |
| Yann Echelard Director | Nov 5, 2024 | 20,000 | $489.50K | Nov 5, 2024 | Open Market Purchase |
| Sagar Lonial Director | Jun 20, 2024 | 7,430 | $125.34K | Jun 20, 2024 | Restricted Stock Vesting |
| Sagar Lonial Director | Jun 20, 2024 | 8,918 | $150.44K | Jun 20, 2024 | Restricted Stock Vesting |
| Sagar Lonial Director | Jun 17, 2024 | 9,585 | $157.12K | Jun 17, 2024 | Restricted Stock Vesting |
| Sagar Lonial Director | Mar 13, 2024 | 5,000 | $79.68K | Mar 13, 2024 | Restricted Stock Vesting |
| Laurence N. Charney Director | Mar 12, 2024 | 22,000 | $351.25K | Mar 12, 2024 | Restricted Stock Vesting |
Congress trades
1 trade in TG Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold (part) | Sep 8, 2020 | $1K–15K | Nov 6, 2020 59 days late |
See a number that looks wrong?